These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30455511)

  • 1. Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis.
    Weyer K; Falzon D; Jaramillo E
    Bull World Health Organ; 2018 Oct; 96(10):667-667A. PubMed ID: 30455511
    [No Abstract]   [Full Text] [Related]  

  • 2. Now is the time for shorter all-oral regimens for multidrug-resistant tuberculosis.
    Seung KJ; Hewison C
    Lancet Glob Health; 2019 Jun; 7(6):e706. PubMed ID: 31005492
    [No Abstract]   [Full Text] [Related]  

  • 3. Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
    Varaine F; Guglielmetti L; Huerga H; Bonnet M; Kiria N; Sitienei JK; Rich M; Mitnick CD
    Am J Respir Crit Care Med; 2016 Oct; 194(8):1028-1029. PubMed ID: 27739887
    [No Abstract]   [Full Text] [Related]  

  • 4. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
    Lange C; Duarte R; Fréchet-Jachym M; Guenther G; Guglielmetti L; Olaru ID; Oliveira O; Rumetshofer R; Veziris N; van Leth F;
    Am J Respir Crit Care Med; 2016 Oct; 194(8):1029-1031. PubMed ID: 27685538
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of regimens for drug-resistant tuberculosis.
    Yates TA; Nunn AJ
    Lancet Infect Dis; 2016 Nov; 16(11):1218-1219. PubMed ID: 27788973
    [No Abstract]   [Full Text] [Related]  

  • 6. Revolutionary new treatment regimens for multidrug-resistant tuberculosis.
    McHugh TD; Honeyborne I; Lipman M; Zumla A
    Lancet Infect Dis; 2019 Mar; 19(3):233-234. PubMed ID: 30833051
    [No Abstract]   [Full Text] [Related]  

  • 7. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis.
    Sotgiu G; Tiberi S; D'Ambrosio L; Centis R; Zumla A; Migliori GB
    Lancet; 2016 Jun; 387(10037):2486-7. PubMed ID: 27353670
    [No Abstract]   [Full Text] [Related]  

  • 8. World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?
    Cox V; Furin J
    Int J Tuberc Lung Dis; 2017 Dec; 21(12):1211-1213. PubMed ID: 29297439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Revised National Tuberculosis Control Programme in India: time for revision of treatment regimens and rapid upscaling of DOTS-plus initiative.
    Bhargava A; Jain Y
    Natl Med J India; 2008; 21(4):187-91. PubMed ID: 19267041
    [No Abstract]   [Full Text] [Related]  

  • 10. Multidrug resistant TB: fully oral regimens should help improve compliance, says WHO.
    Murphy D
    BMJ; 2018 Aug; 362():k3610. PubMed ID: 30131439
    [No Abstract]   [Full Text] [Related]  

  • 11. The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines.
    Caminero JA; García-Basteiro AL; Rendon A; Piubello A; Pontali E; Migliori GB
    Eur Respir J; 2019 Oct; 54(4):. PubMed ID: 31601719
    [No Abstract]   [Full Text] [Related]  

  • 12. [Difficulties in the treatment of pulmonary tuberculosis in children].
    Brînză N; Mihăescu T
    Rev Med Chir Soc Med Nat Iasi; 2007; 111(4):852-5. PubMed ID: 18389769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing the game for multidrug-resistant tuberculosis.
    Ghanashyam B
    Lancet; 2016 Mar; 387(10024):1149-50. PubMed ID: 27025324
    [No Abstract]   [Full Text] [Related]  

  • 14. A new treatment for drug-resistant tuberculosis in Ukraine.
    Holt E
    Lancet Infect Dis; 2022 Jan; 22(1):23. PubMed ID: 34953550
    [No Abstract]   [Full Text] [Related]  

  • 15. Tuberculosis treatment: dangerous regimens?
    Rieder HL; Arnadottir T; Trébucq A; Enarson DA
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract]   [Full Text] [Related]  

  • 16. Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.
    Yassin MA; Jaramillo E; Wandwalo E; Falzon D; Scardigli A; Kunii O; Weyer K
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331045
    [No Abstract]   [Full Text] [Related]  

  • 17. New tuberculosis tests and drugs remain out of reach.
    Makoni M
    Lancet Infect Dis; 2021 Feb; 21(2):174. PubMed ID: 33515522
    [No Abstract]   [Full Text] [Related]  

  • 18. [Not Available].
    Tiberi S; Buchanan R; Caminero JA; Centis R; Arbex MA; Salazar M; Potter J; Migliori GB
    Presse Med; 2017 Mar; 46(2 Pt 2):e41-e51. PubMed ID: 28256383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    van der Werf MJ; Hollo V; Ködmön C; Dara M; Catchpole M
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?
    Kranzer K; Kalsdorf B; Heyckendorf J; Andres S; Merker M; Hofmann-Thiel S; Bloemberg GV; Hoffmann H; Niemann S; Lange C; Maurer FP
    Am J Respir Crit Care Med; 2019 Aug; 200(4):514-515. PubMed ID: 31026398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.